ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 232 filers reported holding ACADIA PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.85 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,087 | -14.3% | 676 | -1.5% | 0.00% | – |
| Q2 2023 | $16,430 | +27.3% | 686 | 0.0% | 0.00% | – |
| Q1 2023 | $12,910 | +18.2% | 686 | 0.0% | 0.00% | – |
| Q4 2022 | $10,921 | +446.0% | 686 | +268.8% | 0.00% | – |
| Q3 2022 | $2,000 | +100.0% | 186 | +48.8% | 0.00% | – |
| Q2 2022 | $1,000 | -93.3% | 125 | -79.1% | 0.00% | – |
| Q1 2022 | $15,000 | -69.4% | 597 | -70.9% | 0.00% | – |
| Q4 2021 | $49,000 | +2350.0% | 2,055 | +1160.7% | 0.00% | – |
| Q3 2021 | $2,000 | -60.0% | 163 | +7.2% | 0.00% | – |
| Q2 2021 | $5,000 | -28.6% | 152 | -37.4% | 0.00% | – |
| Q1 2021 | $7,000 | 0.0% | 243 | +64.2% | 0.00% | – |
| Q4 2020 | $7,000 | -61.1% | 148 | -67.0% | 0.00% | – |
| Q3 2020 | $18,000 | -95.1% | 448 | -94.0% | 0.00% | – |
| Q2 2020 | $364,000 | +5.2% | 7,529 | -8.2% | 0.00% | – |
| Q1 2020 | $346,000 | +200.9% | 8,204 | +207.5% | 0.00% | – |
| Q4 2019 | $115,000 | -97.8% | 2,668 | -98.2% | 0.00% | -100.0% |
| Q3 2019 | $5,213,000 | +3.9% | 144,845 | -22.9% | 0.01% | 0.0% |
| Q2 2019 | $5,019,000 | -39.6% | 187,776 | -39.4% | 0.01% | -37.5% |
| Q1 2019 | $8,315,000 | +30.0% | 309,710 | -21.7% | 0.01% | +14.3% |
| Q4 2018 | $6,398,000 | +127860.0% | 395,674 | +160091.9% | 0.01% | – |
| Q3 2018 | $5,000 | -28.6% | 247 | -41.1% | 0.00% | – |
| Q2 2018 | $7,000 | +75.0% | 419 | +99.5% | 0.00% | – |
| Q1 2018 | $4,000 | -42.9% | 210 | -7.1% | 0.00% | – |
| Q4 2017 | $7,000 | -50.0% | 226 | -38.3% | 0.00% | – |
| Q3 2017 | $14,000 | -65.0% | 366 | -74.1% | 0.00% | – |
| Q2 2017 | $40,000 | -73.3% | 1,411 | -67.8% | 0.00% | – |
| Q1 2017 | $150,000 | +188.5% | 4,384 | +138.8% | 0.00% | – |
| Q4 2016 | $52,000 | +18.2% | 1,836 | +31.1% | 0.00% | – |
| Q3 2016 | $44,000 | -27.9% | 1,400 | -24.2% | 0.00% | – |
| Q2 2016 | $61,000 | +177.3% | 1,848 | +141.3% | 0.00% | – |
| Q1 2016 | $22,000 | -97.5% | 766 | -96.8% | 0.00% | -100.0% |
| Q4 2015 | $863,000 | +58.3% | 24,211 | +46.8% | 0.00% | 0.0% |
| Q3 2015 | $545,000 | -19.1% | 16,490 | +2.5% | 0.00% | 0.0% |
| Q2 2015 | $674,000 | +35.1% | 16,080 | +4.9% | 0.00% | 0.0% |
| Q1 2015 | $499,000 | +731.7% | 15,331 | +712.5% | 0.00% | – |
| Q4 2014 | $60,000 | +33.3% | 1,887 | +2.9% | 0.00% | – |
| Q3 2014 | $45,000 | -80.1% | 1,834 | -81.7% | 0.00% | – |
| Q2 2014 | $226,000 | +14.7% | 10,023 | +24.0% | 0.00% | – |
| Q1 2014 | $197,000 | -26.5% | 8,080 | -24.8% | 0.00% | – |
| Q4 2013 | $268,000 | +16.0% | 10,740 | +27.3% | 0.00% | – |
| Q3 2013 | $231,000 | +1183.3% | 8,440 | +744.0% | 0.00% | – |
| Q2 2013 | $18,000 | – | 1,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |